Filing Flows › Comparisons › IMNM vs AKTS
Immunome vs Aktis Oncology: IMNM and AKTS compared
Immunome is the larger company: $4.0M of revenue in its latest quarter (Q2 2025) against $3.4M for Aktis Oncology (Q2 2026). Aktis Oncology is growing faster (+111% against +70% a year earlier).
Where the money goes: IMNM and AKTS
Immunome (IMNM) · Q2 2025
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
Aktis Oncology (AKTS) · Q2 2026
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
| Immunome (IMNM) | Aktis Oncology (AKTS) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $4.0M | $3.4M |
| Revenue growth, Y/Y | +70% | +111% |
| Operating margin | n/m | -854.0% |
| Net earnings | −$43.4M | −$24.1M |
| Net margin | — | -713.5% |
| Operating cash flow | −$49.4M | −$20.6M |
Questions
Which is bigger, Immunome or Aktis Oncology?
Immunome is the larger company: $4.0M of revenue in its latest quarter (Q2 2025) against $3.4M for Aktis Oncology (Q2 2026).
Is Immunome or Aktis Oncology growing faster?
Aktis Oncology is growing faster (+111% against +70% a year earlier).
More: Immunome earnings · how Immunome makes money · Aktis Oncology earnings · how Aktis Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2025; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.